^
Association details:
| Biomarker: | BCL2 overexpression + MCL1 expression |
|---|---|
| Cancer: | Diffuse Large B Cell Lymphoma |
| Drug: | alrizomadlin (APG-115) (MDM2 inhibitor) + lisaftoclax (APG-2575) (Bcl2 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
A Novel BCL-2 Inhibitor APG-2575 Exerts Synthetic Lethality With BTK or MDM2-p53 Inhibitor in Diffuse Large B-Cell Lymphoma
Published date:
09/01/2020
Excerpt:
We found that APG-2575 combined with APG-115 could synergistically reduce the cells’ viability, and the mean CI values in OCI-LY3 and OCI-LY19 were 0.101 and 0.395, respectively...for those p53 wild-type DLBCL with BCL-2 overexpression and MCL-1 expression, the combination of BCL-2 inhibitor APG-2575 and MDM2-P53 inhibitor APG-115 resulted in a strong antitumor effect.
DOI:
10.3727/096504020X15825405463920
